{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":10,"sponsored":0,"items":[{"id":"n_lookfoo44ozx4fsbzkdq","seq":1399487,"kind":"article","title":"This Nashville name was recently diagnosed with multiple myeloma","url":"https://937kcountry.com/on-air/this-nashville-name-was-recently-diagnosed-with-multiple-myeloma","published":"2026-10-02T17:30:00Z","seen":"2026-10-02T17:39:51Z","lang":"en","source":{"id":"937kcountry.com","name":"937kcountry.com","domain":"937kcountry.com","outlet":{"wikidata":"Q7953816","name":"WOGK","type":"broadcaster","country":"US","designations":["radio station"]}},"via":"gdelt-gkg-english","authors":["kbonet"],"entities":[{"id":"Q467635","name":"multiple myeloma","type":"other"}],"story":"st_lookfoo44ozx4fsbzkdq","category":"health","category_p":0.6,"sentiment":"negative","tone":0.21,"political":0.01},{"id":"n_hmzxbdbbr5ym2fhz5zbq","seq":1398947,"kind":"article","title":"EXCALIBER-RRMM: Iberdomide Improves MRD-Negative CR in R/R Multiple Myeloma","url":"https://www.cancertherapyadvisor.com/news/triplet-therapy-iberdomide-mrd-negative-cr-multiple-myeloma","published":"2026-10-02T15:00:00Z","seen":"2026-10-02T17:39:51Z","lang":"en","source":{"id":"cancertherapyadvisor.com","name":"cancertherapyadvisor.com","domain":"cancertherapyadvisor.com","outlet":{"wikidata":"Q19321823","name":"Cancer Therapy Advisor","type":"newspaper","designations":["newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","science","health"],"entities":[{"id":"Q27271066","name":"iberdomide","type":"other"},{"id":"Q467635","name":"multiple myeloma","type":"other"}],"story":"st_hmzxbdbbr5ym2fhz5zbq","category":"health","category_p":0.66,"sentiment":"positive","tone":-0.03,"political":0.04},{"id":"n_5qmxrpxv62fn3dcc3asa","seq":772283,"kind":"article","title":"Exploring Talquetamab-Based Therapy Before Transplant in Multiple Myeloma","url":"https://www.onclive.com/shorts/exploring-talquetamab-based-therapy-before-transplant-in-multiple-myeloma","published":"2026-09-29T21:45:00Z","seen":"2026-09-29T21:46:54Z","lang":"en","source":{"id":"onclive.com","name":"onclive.com","domain":"onclive.com","outlet":{"wikidata":"Q140944690","name":"OncLive","type":"website","designations":["publication","website"]}},"via":"gdelt-gkg-english","topics":["economy"],"entities":[{"id":"Q116777032","name":"talquetamab","type":"other"},{"id":"Q467635","name":"multiple myeloma","type":"event"}],"story":"st_5qmxrpxv62fn3dcc3asa","category":"health","category_p":0.57,"sentiment":"neutral","tone":-0.36,"political":0.06},{"id":"n_gni4gkend7k6p6kbufpa","seq":694253,"kind":"article","title":"Expanding Community Access to T-Cell Redirecting Therapies in Multiple Myeloma","url":"https://www.onclive.com/view/expanding-community-access-to-t-cell-redirecting-therapies-in-multiple-myeloma","published":"2026-09-29T14:23:21Z","seen":"2026-09-29T14:23:21Z","lang":"en","source":{"id":"onclive.com","name":"onclive.com","domain":"onclive.com","outlet":{"wikidata":"Q140944690","name":"OncLive","type":"website","designations":["publication","website"]}},"via":"gdelt-gkg-english","topics":["economy"],"entities":[{"id":"Q467635","name":"multiple myeloma","type":"event"}],"story":"st_gni4gkend7k6p6kbufpa","category":"health","category_p":0.64,"sentiment":"neutral","tone":0.24,"political":0.05},{"id":"n_qu35o4jwtcezq4qdymdq","seq":694141,"kind":"article","title":"Future Directions in Multiple Myeloma: Emerging Therapies, Sequencing, and the Potential for Cure","url":"https://www.onclive.com/view/future-directions-in-multiple-myeloma-emerging-therapies-sequencing-and-the-potential-for-cure","published":"2026-09-29T14:23:21Z","seen":"2026-09-29T14:23:21Z","lang":"en","source":{"id":"onclive.com","name":"onclive.com","domain":"onclive.com","outlet":{"wikidata":"Q140944690","name":"OncLive","type":"website","designations":["publication","website"]}},"via":"gdelt-gkg-english","topics":["economy"],"entities":[{"id":"Q467635","name":"multiple myeloma","type":"event"}],"story":"st_qu35o4jwtcezq4qdymdq","category":"health","category_p":0.52,"sentiment":"neutral","tone":0.37,"political":0.02},{"id":"n_4hilmdkcn5fgoy3xeg4a","seq":560750,"kind":"article","title":"Could Bristol-Myers Squibb (BMY)'s New Myeloma Data Reshape its Growth Outlook?","url":"https://www.insidermonkey.com/news/could-bristol-myers-squibb-bmys-new-myeloma-data-reshape-its-growth-outlook-1846025","published":"2026-09-29T02:15:00Z","seen":"2026-09-29T02:20:13Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["economy","business","science","disaster"],"authors":["Laiba Immad"],"entities":[{"id":"Q266423","name":"Bristol-Myers Squibb","type":"org"},{"id":"Q8078626","name":"Île Art – Waala Airport","type":"org"},{"id":"Q467635","name":"multiple myeloma","type":"other"}],"story":"st_4hilmdkcn5fgoy3xeg4a","category":"economy-business","category_p":0.36,"category2":"health","sentiment":"neutral","tone":-0.15,"political":0.03},{"id":"n_tf3nrhf3uyo5kyevsapq","seq":520991,"kind":"article","title":"What Will it Take to Use the Word Cure in Myeloma?","url":"https://www.onclive.com/shorts/what-will-it-take-to-use-the-word-cure-in-myeloma-","published":"2026-09-28T20:50:16Z","seen":"2026-09-28T20:50:16Z","lang":"en","source":{"id":"onclive.com","name":"onclive.com","domain":"onclive.com","outlet":{"wikidata":"Q140944690","name":"OncLive","type":"website","designations":["publication","website"]}},"via":"gdelt-gkg-english","topics":["economy"],"entities":[{"id":"Q467635","name":"multiple myeloma","type":"other"}],"story":"st_tf3nrhf3uyo5kyevsapq","category":"health","category_p":0.74,"sentiment":"neutral","tone":-0.4,"political":0.03},{"id":"n_gxp5x4use5jgy4elzuna","seq":520849,"kind":"article","title":"Dr van Esser on the Toxicity Profile Associated With Carfilzomib/Lenalidomide/Dexamethasone in Myeloma","url":"https://www.onclive.com/view/dr-van-esser-on-the-toxicity-profile-associated-with-carfilzomib-lenalidomide-dexamethasone-in-myeloma","published":"2026-09-28T20:50:16Z","seen":"2026-09-28T20:50:16Z","lang":"en","source":{"id":"onclive.com","name":"onclive.com","domain":"onclive.com","outlet":{"wikidata":"Q140944690","name":"OncLive","type":"website","designations":["publication","website"]}},"via":"gdelt-gkg-english","topics":["health","economy"],"entities":[{"id":"Q467635","name":"multiple myeloma","type":"other"}],"story":"st_gxp5x4use5jgy4elzuna","category":"health","category_p":0.6,"sentiment":"neutral","tone":-0.61,"political":0.07},{"id":"n_jw334vgxvglg237z2exq","seq":519889,"kind":"article","title":"Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma","url":"https://www.onclive.com/view/dr-voorhees-on-eligibility-criteria-for-the-cervino-trial-in-multiple-myeloma","published":"2026-09-28T20:50:16Z","seen":"2026-09-28T20:50:16Z","lang":"en","source":{"id":"onclive.com","name":"onclive.com","domain":"onclive.com","outlet":{"wikidata":"Q140944690","name":"OncLive","type":"website","designations":["publication","website"]}},"via":"gdelt-gkg-english","topics":["economy","health","education"],"entities":[{"id":"Q467635","name":"multiple myeloma","type":"event"}],"story":"st_jw334vgxvglg237z2exq","category":"health","category_p":0.58,"sentiment":"neutral","tone":-0.08,"political":0.1},{"id":"n_auwijsyognsekrme7qgq","seq":492839,"kind":"press_release","title":"Una nuova analisi basata su modelli conferma ulteriormente il potenziale di TECVAYLI®▼ (teclistamab) in associazione con daratumumab nel ridefinire le aspettative di sopravvivenza a lungo termine nel mieloma multiplo recidivante/refrattario trattato in prima linea","url":"https://www.globenewswire.com/news-release/2026/09/28/3370197/0/it/una-nuova-analisi-basata-su-modelli-conferma-ulteriormente-il-potenziale-di-tecvayli-teclistamab-in-associazione-con-daratumumab-nel-ridefinire-le-aspettative-di-sopravvivenza-a-lu.html","summary":"BEERSE, Belgio, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson, leader mondiale nel campo del trattamento del mieloma multiplo, ha annunciato oggi nuovi dati provenienti dallo studio di Fase 3 MajesTEC-3, che dimostrano un controllo della malattia e una sopravvivenza duraturi con TECVAYLI ® (teclistamab) in associazione con daratumumab nei pazienti affetti da mieloma multiplo recidivante o refrattario (RRMM) che avevano precedentemente ricevuto da 1 a 3 linee di…","published":"2026-09-28T17:58:00Z","seen":"2026-09-28T18:02:52Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q5222113","name":"daratumumab","type":"other"},{"id":"Q467635","name":"multiple myeloma","type":"other"}],"story":"st_oisedendgjk4a3yuhoaq","category":"health","category_p":0.56,"sentiment":"neutral","tone":0.26,"political":0.02}]}